Contact
searchSearch
HMP Global

ACTRIMS Meeting Newsroom

Conference Coverage
Study Links MS-Related Fatigue to Disability Status and Lower Quality of Life
03/13/2025
Grace Taylor, MS, MA
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is...
03/13/2025
First Report Managed Care
Conference Coverage
Study Examines the Effects of MS Treatment on Mobility and Emergency Care
03/13/2025
Juliet Gallagher
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
Ozanimod Shows Promise in Preserving Brain Volume in Patients With Early Relapsing MS
03/04/2025
Hannah Musick
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
Immunomodulatory Effects of Modified Atkins Diet in Patients With Multiple Sclerosis
03/04/2025
Hannah Musick
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
MSDA Test Helps Guide Multiple Sclerosis Treatment Decisions, Study Finds
02/28/2025
Grace Taylor, MS, MA
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test...
02/28/2025
First Report Managed Care
Conference Coverage
Study Finds No Treatment Disparities in MS Care Between Medicaid and Private Insurance
02/28/2025
Grace Taylor, MS, MA
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025...
02/28/2025
First Report Managed Care
Conference Coverage
The Clinical and Economic Burden of Primary Progressive Multiple Sclerosis
02/27/2025
Grace Taylor, MS, MA
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the...
02/27/2025
First Report Managed Care
Conference Coverage
Leveraging AI for Multiple Sclerosis Diagnosis
02/27/2025
Grace Taylor, MS, MA
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s...
02/27/2025
First Report Managed Care

Conference Coverage
Study Links MS-Related Fatigue to Disability Status and Lower Quality of Life
03/13/2025
Grace Taylor, MS, MA
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is...
03/13/2025
First Report Managed Care
Conference Coverage
Study Examines the Effects of MS Treatment on Mobility and Emergency Care
03/13/2025
Juliet Gallagher
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
Ozanimod Shows Promise in Preserving Brain Volume in Patients With Early Relapsing MS
03/04/2025
Hannah Musick
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
Immunomodulatory Effects of Modified Atkins Diet in Patients With Multiple Sclerosis
03/04/2025
Hannah Musick
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
MSDA Test Helps Guide Multiple Sclerosis Treatment Decisions, Study Finds
02/28/2025
Grace Taylor, MS, MA
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test...
02/28/2025
First Report Managed Care
Conference Coverage
Study Finds No Treatment Disparities in MS Care Between Medicaid and Private Insurance
02/28/2025
Grace Taylor, MS, MA
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025 ACTRIMS Forum shows that individuals with Medicaid receive similar high-efficacy treatment for multiple sclerosis as those with private insurance, supporting Medicaid’s role in promoting health equity.
A study presented at the 2025...
02/28/2025
First Report Managed Care
Conference Coverage
The Clinical and Economic Burden of Primary Progressive Multiple Sclerosis
02/27/2025
Grace Taylor, MS, MA
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the significant health care challenges and costs associated with primary progressive multiple sclerosis (PPMS).
New research highlights the...
02/27/2025
First Report Managed Care
Conference Coverage
Leveraging AI for Multiple Sclerosis Diagnosis
02/27/2025
Grace Taylor, MS, MA
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s ability to classify multiple sclerosis diagnosis from clinical notes, finding promising but imperfect results with 74% overall accuracy.
Researchers tested GPT-4’s...
02/27/2025
First Report Managed Care
Conference Coverage
IRA Implementation and the Financial Rewiring of Medicare Part D
03/11/2026
Hannah Musick
As the Inflation Reduction Act (IRA) fundamentally restructures Medicare Part D financing, payers and manufacturers are recalibrating bid strategies, contracting models, and formulary decision-making ahead of 2026 implementation milestones.
As the Inflation Reduction Act (IRA) fundamentally restructures Medicare Part D financing, payers and manufacturers are recalibrating bid strategies, contracting models, and formulary decision-making ahead of 2026 implementation milestones.
As the Inflation Reduction Act...
03/11/2026
First Report Managed Care
Conference Coverage
Specialty Drug Strategy in a High-Cost, High-Scrutiny Environment
03/10/2026
Hannah Musick
As oncology, rare disease, and gene therapy pipelines expand, managed care leaders are recalibrating specialty drug strategies to manage escalating costs while preserving patient access and clinical innovation.
As oncology, rare disease, and gene therapy pipelines expand, managed care leaders are recalibrating specialty drug strategies to manage escalating costs while preserving patient access and clinical innovation.
As oncology, rare disease, and...
03/10/2026
First Report Managed Care
Conference Coverage
Navigating the New Affordability Landscape: PDABs, Copay Programs, and Alternative Funding Models
03/09/2026
Hannah Musick
As states expand Prescription Drug Affordability Review Board (PDAB) authority and copay accumulator bans gain traction, managed care stakeholders are reassessing benefit design, reimbursement strategy, and contracting models in response to a...
As states expand Prescription Drug Affordability Review Board (PDAB) authority and copay accumulator bans gain traction, managed care stakeholders are reassessing benefit design, reimbursement strategy, and contracting models in response to a...
As states expand Prescription...
03/09/2026
First Report Managed Care
Conference Coverage
AI and Real-World Evidence in Pharmacy Benefit Decision-Making
03/09/2026
Hannah Musick
Growing reliance on advanced analytics and real-world evidence is redefining reimbursement evaluation, prior authorization efficiency, and value-based contracting—signaling a shift toward more data-driven pharmacy benefit management.
Growing reliance on advanced analytics and real-world evidence is redefining reimbursement evaluation, prior authorization efficiency, and value-based contracting—signaling a shift toward more data-driven pharmacy benefit management.
Growing reliance on advanced...
03/09/2026
First Report Managed Care
Conference Coverage
Exercise Boosts Daily Activity Beyond Workouts in Older Adults With Obesity, Study Finds
11/06/2025
Grace Taylor, MS, MA
A study presented at ObesityWeek 2025 shows that adding structured exercise to calorie-restricted weight loss plans significantly increases daily, non-exercise physical activity in older adults with obesity.
A study presented at ObesityWeek 2025 shows that adding structured exercise to calorie-restricted weight loss plans significantly increases daily, non-exercise physical activity in older adults with obesity.
A study presented at ObesityWeek...
11/06/2025
First Report Managed Care
Conference Coverage
GLP-1 Receptor Agonist Drug Trends Analyzed via AI
11/06/2025
Hannah Musick
A novel artificial intelligence (AI)-driven meta-analysis of obesity drug trials presented at ObesityWeek 2025 highlighted that GLP-1 receptor agonists and emerging multi-receptor therapies offer the greatest weight loss efficacy to date,...
A novel artificial intelligence (AI)-driven meta-analysis of obesity drug trials presented at ObesityWeek 2025 highlighted that GLP-1 receptor agonists and emerging multi-receptor therapies offer the greatest weight loss efficacy to date,...
A novel artificial intelligence...
11/06/2025
First Report Managed Care
Conference Coverage
GLP-1 RA Access Improved Through Specialty Pharmacy Collaboration
11/05/2025
Hannah Musick
A quality improvement initiative demonstrated that partnering with an integrated specialty pharmacy significantly increased GLP-1 RA prescription fulfillment and patient enrollment in a pediatric obesity clinic, streamlining access and...
A quality improvement initiative demonstrated that partnering with an integrated specialty pharmacy significantly increased GLP-1 RA prescription fulfillment and patient enrollment in a pediatric obesity clinic, streamlining access and...
A quality improvement initiative...
11/05/2025
First Report Managed Care
Conference Coverage
Oral GLP-1 Receptor Agonist Bofanglutide Shows Promising Results
11/05/2025
Hannah Musick
Oral bofanglutide demonstrated favorable safety, dose-dependent exposure, and meaningful weight reduction over 14 days, supporting its potential as a once-daily GLP-1 receptor agonist therapy for type 2 diabetes and obesity.
Oral bofanglutide demonstrated favorable safety, dose-dependent exposure, and meaningful weight reduction over 14 days, supporting its potential as a once-daily GLP-1 receptor agonist therapy for type 2 diabetes and obesity.
Oral bofanglutide demonstrated...
11/05/2025
First Report Managed Care
News
GLP-1 Receptor Agonists Linked to Reduced Unhealthy Alcohol Use Among Veterans With Type 2 Diabetes
11/04/2025
Grace Taylor, MS, MA
A study presented at ObesityWeek by the Veterans Health Administration found that patients with type 2 diabetes taking GLP-1 receptor agonists showed significantly lower rates of unhealthy alcohol use, suggesting potential behavioral benefits...
A study presented at ObesityWeek by the Veterans Health Administration found that patients with type 2 diabetes taking GLP-1 receptor agonists showed significantly lower rates of unhealthy alcohol use, suggesting potential behavioral benefits...
A study presented at ObesityWeek...
11/04/2025
First Report Managed Care
Conference Coverage
GLP-1 Receptor Agonists Linked to Lower Mortality and Increased Transplant Waitlisting in Dialysis Patients With Diabetes
11/04/2025
Hannah Musick
In a national cohort study presented at ObesityWeek 2025, GLP-1 receptor agonist use in dialysis patients with type 2 diabetes was associated with lower mortality, greater weight loss, and increased likelihood of transplant waitlisting,...
In a national cohort study presented at ObesityWeek 2025, GLP-1 receptor agonist use in dialysis patients with type 2 diabetes was associated with lower mortality, greater weight loss, and increased likelihood of transplant waitlisting,...
In a national cohort study...
11/04/2025
First Report Managed Care

What's New?

Conference Coverage
Study Links MS-Related Fatigue to Disability Status and Lower Quality of Life
03/13/2025
Grace Taylor, MS, MA
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is strongly linked to lower quality of life, particularly in those with higher disability scores, and decreased work capacity, according to recent research.
Fatigue in multiple sclerosis is...
03/13/2025
First Report Managed Care
Conference Coverage
Study Examines the Effects of MS Treatment on Mobility and Emergency Care
03/13/2025
Juliet Gallagher
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study...
03/13/2025
First Report Managed Care
Conference Coverage
Ozanimod Shows Promise in Preserving Brain Volume in Patients With Early Relapsing MS
03/04/2025
Hannah Musick
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in...
03/04/2025
First Report Managed Care
Conference Coverage
Immunomodulatory Effects of Modified Atkins Diet in Patients With Multiple Sclerosis
03/04/2025
Hannah Musick
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a...
03/04/2025
First Report Managed Care
Conference Coverage
MSDA Test Helps Guide Multiple Sclerosis Treatment Decisions, Study Finds
02/28/2025
Grace Taylor, MS, MA
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test helps guide treatment decisions in multiple sclerosis based on objective changes in treatment plan and clinician reported impact, according to a study presented at the 2025 ACTRIMS Forum.
The MS Disease Activity test...
02/28/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use